The central THαβ immunity associated cytokine: IL-10 has a strong anti-tumor ability toward established cancer models in vivo and toward cancer cells in vitro

Author:

Hu Wan-Chung

Abstract

AbstractCancer immunotherapy is a promising new approach for cancer treatment. We propose to use a new host immunological pathway: THαβ immunity for cancer treatment. THαβ immunity is a natural host immunity which can be used IFN-α/β and its major effectors are IL-10 and IL-15. Thus, we here used these cytokines for treatment both in a mice breast cancer 4T1 model and in a neuroblastoma NXS2 model. 4T1 cells and NXS2 cells were inoculated subcutaneously to wild type BALB/c female mice and AJ mice, respectively. Both Cytokines and an antibody treatment with variable dosages were given. Our results show that IL-10 and IL-15 treatments have significant effects on not only tumor volume shrinkage and but also on mice survival. However, IFN-γ even worsens the tumor volume and mice survival. Antibodies plus IL-10 is no better than IL-10 alone for cancer immunotherapy. This can be due to GD2 antigen expression on immune cells. Moreover, an anti-GD2 antibody could harm immune cells themselves. We found that IL-10 has direct toxicity on tumor cells in vitro. Our results conclude that using THαβ immunity is a good strategy for cancer immunotherapy.

Publisher

Cold Spring Harbor Laboratory

Reference26 articles.

1. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins;J Immunol,1986

2. Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

3. The role of cytokines (and not only) in inducing and expanding T regulatory type 1 cells.

4. Mouse 4T1 breast tumor model;Curr Protoc Immunol Chapter,2001

5. Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3